Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice.
about
Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-beta-deficient neutrophils in a congenital neutropenia syndromeModulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsResveratrol and Its Metabolites Bind to PPARsPeroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzymePomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator propertiesProteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interactionMutation screen and association studies in the diacylglycerol O-acyltransferase homolog 2 gene (DGAT2), a positional candidate gene for early onset obesity on chromosome 11q13.Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats.Nonhuman primates and other animal models in diabetes research.Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors.Diabetes trends in Japan.Lipoprotein lipase: from gene to obesity.Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approachNitrooleic Acid Attenuates Lipid Metabolic Disorders and Liver Steatosis in DOCA-Salt Hypertensive Mice.55-week treatment of mice with the unani and ayurvedic medicine pomegranate flower ameliorates ageing-associated insulin resistance and skin abnormalities.Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studiesSignificance of anti-inflammatory effects of PPARgamma agonists?Inhibition of Dexamethasone-induced Fatty Liver Development by Reducing miR-17-5p Levels.Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's DiseaseMolecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review.Mechanism of the anti-platelet effect of natural bioactive compounds: role of peroxisome proliferator-activated receptors activation.Genetic basis of interindividual susceptibility to cancer cachexia: selection of potential candidate gene polymorphisms for association studies.AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Transcription factor AP1 binds the functional region of the promoter and regulates gene expression of human PPARdelta in LoVo cell.Homocysteine-mediated cholesterol efflux via ABCA1 and ACAT1 DNA methylation in THP-1 monocyte-derived foam cells.Peroxisome proliferator-activated receptor (PPAR) α and δ activators induce ICAM-1 expression in quiescent non stimulated endothelial cells.AP1-dependent repression of TGFα-mediated MMP9 upregulation by PPARδ agonists in keratinocytes.DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury.Carvacrol ameliorates the PPAR-A and cytochrome P450 expression on D-galactosamine induced hepatotoxicity rats.Peroxisome proliferator-activated receptor {delta} activators induce IL-8 expression in nonstimulated endothelial cells in a transcriptional and posttranscriptional manner.Influence of apolipoprotein E polymorphism on plasma vitamin A and vitamin E levels.Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator.Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice.Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice.Ligand activation of peroxisome proliferator-activated receptor delta suppresses cathepsin B expression in human endothelial cells in a posttranslational manner.Effects of gemfibrozil treatment on vascular reactivity of streptozotocin-diabetic rat aorta.
P2860
Q24613779-5EC478DF-DAE2-4491-A66A-29D4172C2A5DQ26829098-9FE40653-A0B6-4BE5-B3B6-B7E2A5ADD918Q27683643-39381535-EE2A-4638-8C5E-3A7A76A0B6B5Q28179772-9ABE3AEE-AF08-409A-BA0C-07E2040EE8E9Q28261771-15DDBB22-F917-4C41-B25A-9F4AB2931402Q28484038-E72AF680-8B45-49FC-ACC3-52933AC85046Q33283626-EE70FBE9-3285-499C-ADF2-0CA006A1F7F3Q34021895-605556C7-03DF-465D-BC70-65A9AA7CD955Q34286456-9D227E3F-44EC-4D01-A337-70443F621EB5Q34339895-B9A475EE-68A5-4169-BB1F-11AB7CB965D3Q34906275-61965FD0-FED5-4F6E-80CF-700156B2F5E6Q34968373-03EC3309-CA87-47F7-9BEA-FE4B41BD93B2Q35104849-6D6019A0-1119-47C8-80A5-F07A88D87C09Q35227098-8ECBB1C4-BA77-4606-935E-BDA6B5ADCA4CQ35664389-BF5EBBC5-5138-427F-9751-C4BB78C21F10Q35754362-0F151985-D62C-4E7C-9C42-5362E062FCAAQ36540016-E50FCD2C-81C2-48C4-8291-5501A90A4F47Q36756799-32EAE0E8-9C0E-4A1B-B53B-80D2FA1369AFQ37211800-18021136-FA59-4EB9-9BB8-1F6DCC1DDA2BQ37254899-9C84C83F-779E-4255-AE7F-1ACBD0D35C15Q37890195-77B1EE26-8F4F-4B66-9E68-FBFB1811EDE3Q38163612-FEBEC33E-5AE6-4A25-BF4C-00E5FC3CD6C1Q38311787-42F83721-494E-46F9-8BC4-C71B926777C2Q38361567-8DEC64A2-12CE-490F-8100-0E6E14D9FDF4Q38546242-575EA907-8DAD-4E45-8658-5AFC72E11890Q39129199-BCD7171F-4D63-4DF0-A04C-84F86F963F9FQ39213031-26063F8D-AD74-4787-98A9-FADB120B932EQ39468345-4A2E18D9-80EF-4437-BD9A-B512BD10C258Q39558302-A31D1635-3EB2-4C6B-8B93-9EA5EA93338CQ40671125-A28BD277-FE58-47E4-8DEE-B2472E30A33CQ40671179-02643650-8520-4F1A-BFBC-8D51EB5EE842Q41886732-FEC9ABF2-96FB-4A8B-A189-53B14FF56710Q42015969-55A8EABD-57B9-4B57-A229-06AFB3CD912DQ42400879-CB5BA3D9-2BAE-4210-9D62-A20BBF115424Q43959120-2CFC2D85-E10B-45E7-B85E-128F33E02614Q44103914-C5E95F0D-CF6B-4943-9004-2391D10DBB00Q44177995-005BF7DD-1B47-45D9-83C5-58F9D8C0B49CQ44269051-78301612-B070-40CD-9838-9890CC0994C4Q44374642-D1451401-12B4-4427-8FBE-1532BDB402AAQ44789811-6B2F299E-560B-4744-9A74-AA5E2C89E14D
P2860
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Peroxisome proliferator-activa ...... control to clinical practice.
@ast
Peroxisome proliferator-activa ...... control to clinical practice.
@en
Peroxisome proliferator-activa ...... control to clinical practice.
@nl
type
label
Peroxisome proliferator-activa ...... control to clinical practice.
@ast
Peroxisome proliferator-activa ...... control to clinical practice.
@en
Peroxisome proliferator-activa ...... control to clinical practice.
@nl
prefLabel
Peroxisome proliferator-activa ...... control to clinical practice.
@ast
Peroxisome proliferator-activa ...... control to clinical practice.
@en
Peroxisome proliferator-activa ...... control to clinical practice.
@nl
P2093
P1476
Peroxisome proliferator-activa ...... control to clinical practice.
@en
P2093
P304
P356
10.1097/00041433-200106000-00002
P50
P577
2001-06-01T00:00:00Z